Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.89
EBS's Cash to Debt is ranked higher than
63% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. EBS: 2.89 )
EBS' s 10-Year Cash to Debt Range
Min: 0.53   Max: No Debt
Current: 2.89

Equity to Asset 0.78
EBS's Equity to Asset is ranked higher than
81% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EBS: 0.78 )
EBS' s 10-Year Equity to Asset Range
Min: -1.27   Max: 0.78
Current: 0.78

-1.27
0.78
F-Score: 7
Z-Score: 5.44
M-Score: -3.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.69
EBS's Operating margin (%) is ranked higher than
88% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. EBS: 13.69 )
EBS' s 10-Year Operating margin (%) Range
Min: -0.8   Max: 48.09
Current: 13.69

-0.8
48.09
Net-margin (%) 9.96
EBS's Net-margin (%) is ranked higher than
88% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. EBS: 9.96 )
EBS' s 10-Year Net-margin (%) Range
Min: -1.22   Max: 46.34
Current: 9.96

-1.22
46.34
ROE (%) 6.36
EBS's ROE (%) is ranked higher than
87% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. EBS: 6.36 )
EBS' s 10-Year ROE (%) Range
Min: 5.33   Max: 875.86
Current: 6.36

5.33
875.86
ROA (%) 4.97
EBS's ROA (%) is ranked higher than
88% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. EBS: 4.97 )
EBS' s 10-Year ROA (%) Range
Min: -2.18   Max: 159.68
Current: 4.97

-2.18
159.68
ROC (Joel Greenblatt) (%) 14.20
EBS's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. EBS: 14.20 )
EBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.79   Max: 69.62
Current: 14.2

9.79
69.62
Revenue Growth (%) -1.10
EBS's Revenue Growth (%) is ranked higher than
74% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. EBS: -1.10 )
EBS' s 10-Year Revenue Growth (%) Range
Min: -1.1   Max: 31.4
Current: -1.1

-1.1
31.4
EBITDA Growth (%) -11.30
EBS's EBITDA Growth (%) is ranked higher than
72% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. EBS: -11.30 )
EBS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 20.9
Current: -11.3

0
20.9
EPS Growth (%) -18.80
EBS's EPS Growth (%) is ranked higher than
69% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. EBS: -18.80 )
EBS' s 10-Year EPS Growth (%) Range
Min: -26.7   Max: 61.7
Current: -18.8

-26.7
61.7
» EBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

EBS Guru Trades in Q1 2013

Paul Tudor Jones 32,900 sh (New)
Jim Simons 905,611 sh (+79.65%)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Ken Fisher 397,270 sh (-1.1%)
Chuck Royce 103,761 sh (-22.8%)
» More
Q2 2013

EBS Guru Trades in Q2 2013

Steven Cohen 530,665 sh (New)
John Rogers 27,500 sh (New)
Ken Fisher 393,595 sh (-0.93%)
Jim Simons 723,811 sh (-20.07%)
Paul Tudor Jones 21,900 sh (-33.43%)
Chuck Royce 30,386 sh (-70.72%)
» More
Q3 2013

EBS Guru Trades in Q3 2013

John Rogers 59,600 sh (+116.73%)
Steven Cohen 853,748 sh (+60.88%)
Ken Fisher 434,195 sh (+10.32%)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jim Simons 597,511 sh (-17.45%)
» More
Q4 2013

EBS Guru Trades in Q4 2013

John Rogers 122,650 sh (+105.79%)
Steven Cohen 913,816 sh (+7.04%)
Jim Simons 563,611 sh (-5.67%)
Ken Fisher 399,595 sh (-7.97%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Sold Out 0.14%$13.95 - $16.9 $ 25.160%0
Joel Greenblatt 2012-12-31 New Buy0.14%$12.91 - $16.09 $ 25.171%147099
Joel Greenblatt 2011-12-31 Sold Out 0.08%$15.43 - $19.64 $ 25.144%0
Joel Greenblatt 2011-06-30 Reduce -20.74%0.05%$20.66 - $24.98 $ 25.18%26620
Joel Greenblatt 2011-03-31 Add 243.58%0.17%$20.64 - $24.55 $ 25.111%33585
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.00
EBS's P/E(ttm) is ranked higher than
68% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. EBS: 30.00 )
EBS' s 10-Year P/E(ttm) Range
Min: 6.72   Max: 37.1
Current: 30

6.72
37.1
P/B 1.80
EBS's P/B is ranked higher than
88% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. EBS: 1.80 )
EBS' s 10-Year P/B Range
Min: 0.84   Max: 3.82
Current: 1.8

0.84
3.82
P/S 2.95
EBS's P/S is ranked higher than
84% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. EBS: 2.95 )
EBS' s 10-Year P/S Range
Min: 0.81   Max: 4.34
Current: 2.95

0.81
4.34
PFCF 17.10
EBS's PFCF is ranked higher than
82% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. EBS: 17.10 )
EBS' s 10-Year PFCF Range
Min: 5.52   Max: 748.33
Current: 17.1

5.52
748.33
EV-to-EBIT 18.50
EBS's EV-to-EBIT is ranked higher than
61% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. EBS: 18.50 )
EBS' s 10-Year EV-to-EBIT Range
Min: 3.3   Max: 31.9
Current: 18.5

3.3
31.9
PEG 4.30
EBS's PEG is ranked lower than
53% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. EBS: 4.30 )
EBS' s 10-Year PEG Range
Min: 0.13   Max: 66.15
Current: 4.3

0.13
66.15
Shiller P/E 27.10
EBS's Shiller P/E is ranked higher than
79% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. EBS: 27.10 )
EBS' s 10-Year Shiller P/E Range
Min: 13.29   Max: 29.86
Current: 27.1

13.29
29.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.60
EBS's Price/Net Cash is ranked lower than
68% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. EBS: 21.60 )
EBS' s 10-Year Price/Net Cash Range
Min: 19.82   Max: 46
Current: 21.6

19.82
46
Price/Net Current Asset Value 9.20
EBS's Price/Net Current Asset Value is ranked higher than
55% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. EBS: 9.20 )
EBS' s 10-Year Price/Net Current Asset Value Range
Min: 5.82   Max: 22.13
Current: 9.2

5.82
22.13
Price/Tangible Book 2.30
EBS's Price/Tangible Book is ranked higher than
87% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. EBS: 2.30 )
EBS' s 10-Year Price/Tangible Book Range
Min: 0.88   Max: 3.92
Current: 2.3

0.88
3.92
Price/DCF (Projected) 1.90
EBS's Price/DCF (Projected) is ranked higher than
82% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. EBS: 1.90 )
EBS' s 10-Year Price/DCF (Projected) Range
Min: 1.54   Max: 2.83
Current: 1.9

1.54
2.83
Price/Median PS Value 1.40
EBS's Price/Median PS Value is ranked higher than
53% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. EBS: 1.40 )
EBS' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 2.14
Current: 1.4

0.41
2.14
Price/Graham Number 1.70
EBS's Price/Graham Number is ranked higher than
79% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. EBS: 1.70 )
EBS' s 10-Year Price/Graham Number Range
Min: 0.51   Max: 2.61
Current: 1.7

0.51
2.61
Earnings Yield (Greenblatt) 5.40
EBS's Earnings Yield (Greenblatt) is ranked higher than
67% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. EBS: 5.40 )
EBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 30.2
Current: 5.4

3.1
30.2
Forward Rate of Return (Yacktman) 1.42
EBS's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. EBS: 1.42 )
EBS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.7   Max: 111.4
Current: 1.42

-14.7
111.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ER4.Germany
Emergent BioSolutions Inc. was incorporated as BioPort Corporation under the laws of Michigan in May 1998. In June 2004, it completed a corporate reorganization in which Emergent BioSolutions Inc., a Delaware corporation formed in December 2003, issued shares of class A common stock to stockholders of BioPort in exchange for an equal number of outstanding shares of common stock of BioPort. As a result of this reorganization, BioPort became the Company's wholly owned subsidiary. It subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Emergent BioSolutions Inc. is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and commercial. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's commercial segment focuses on vaccines and therapeutics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Its product candidates in this segment include a typhoid vaccine, a tuberculosis vaccine, a hepatitis B therapeutic vaccine and a chlamydia vaccine. The Company faces competition with respect to BioThrax, its current product candidates from major pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research institutions that conduct research, seek patent protection and establish collaborative arrangemen

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide